Premium
Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease
Author(s) -
Sutphen Courtney L.,
McCue Lena,
Herries Elizabeth M.,
Xiong Chengjie,
Ladenson Jack H.,
Holtzman David M.,
Fagan Anne M.
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.01.012
Subject(s) - biomarker , disease , alzheimer's disease neuroimaging initiative , cerebrospinal fluid , medicine , neuroinflammation , oncology , neuroimaging , clinical trial , alzheimer's disease , amyloid (mycology) , cognition , population , psychology , pathology , psychiatry , biology , biochemistry , environmental health
Individuals in early stages of Alzheimer's disease are a targeted population for secondary prevention trials aimed at preserving normal cognition. Understanding within‐person biomarker(s) change over time is critical for trial enrollment and design. Methods Longitudinal cerebrospinal fluid samples from the Alzheimer's Disease Neuroimaging Initiative were assayed for novel markers of neuronal/synaptic injury (visinin‐like protein 1, Ng, and SNAP‐25) and neuroinflammation (YKL‐40) and compared with β amyloid 42, tau, and phospho‐tau181. General linear mixed models were used to compare within‐person rates of change in three clinical groups (cognitively normal, mild cognitive impairment, and Alzheimer's disease) further defined by β amyloid status. Results Levels of injury markers were highly positively correlated. Despite elevated baseline levels as a function of clinical status and amyloid‐positivity, within‐person decreases in these measures were observed in the early symptomatic, amyloid‐positive Alzheimer's disease group. Discussion Knowledge of within‐person biomarker change will impact interpretation of biomarker outcomes in clinical trials that are dependent on disease stage.